Anzeige
Mehr »
Login
Dienstag, 21.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Aktienchance des Jahres! Ihre Chance auf explosive Gewinne!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1H43V | ISIN: SE0003086214 | Ticker-Symbol: M16
Frankfurt
20.01.25
09:21 Uhr
0,004 Euro
-0,013
-78,82 %
Branche
Elektrotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
METACON AB Chart 1 Jahr
5-Tage-Chart
METACON AB 5-Tage-Chart
RealtimeGeldBriefZeit
0,0040,01620.01.
PR Newswire
404 Leser
Artikel bewerten:
(2)

Metacon AB: Metacon publishes interim report for Q3 2024

Finanznachrichten News

STOCKHOLM, Nov. 19, 2024 /PRNewswire/ -- In the third quarter, we were pleased to announce that we had entered into an agreement for the sale and delivery of a 30 MW electrolysis plant to Motor Oil, in Greece. It is a breakthrough in our strategy to become a leading manufacturer and supplier in the field of industrial hydrogen production. The project for Motor Oil is an important step in our work to develop and license manufacture electrolysis plants for large-scale hydrogen production. Metacon's own production of system products will begin already within the framework of this project as we will use our existing factory and staff in Greece. The project has further growth potential as Motor Oil has the opportunity to expand the plant by an additional 20 MW in a second phase.

For the full CEO-comment, see the Interim report in its entirety.

Quarter July-September

  • Revenues amounted to SEK 6.1 (21.6) million
  • Earnings before depreciation and amortization (EBITDA) amounted to SEK -46.3 (-16.9) million
  • Operating profit (EBIT) amounted to SEK -49.1 (-19.6) million
  • Profit/Loss after financial items amounted to SEK -49.3 (-19.9) million
  • Earnings per share amounted to SEK -0.07 (-0.06)

Period January-September

  • Revenues amounted to SEK 26.0 (65.8) million
  • Earnings before depreciation and amortization (EBITDA) amounted to SEK -89.6 (-44.6) million
  • Operating profit (EBIT) amounted to SEK -97.9 (-52.7) million
  • Profit/Loss after financial items amounted to SEK -99.4 (-53.4) million
  • Earnings per share amounted to SEK -0.15 (-0.16)

Events during and after the quarter

  • On August 8, it is announced that Metacon has entered into an agreement for the delivery of a 30 MW industrial electrolysis plant worth EUR 19.8 million (approx. SEK 226 million) and marks the start of our European manufacturing of electrolyzers.
  • On September 10, it is announced that Nikolett Sipöcz will take up the position as Chief Business Officer Electrolysis for Metacon with effect from November 4, 2024. She replaces Johan Berggren in his manager role as Head of Sales, which enables Johan to have full focus on sales and business development work towards major key projects in the role of Business Development Director.
  • On October 15, it is announced that the board of Metacon has decided on a rights issue of approximately SEK 138 million, which was approved by the Extraordinary General Meeting on November 15.

Contact
Christer Wikner, President & CEO, +46 707 647 389, christer.wikner@metacon.com
Mattias Jansson, CFO, +46 722 316 862 Mattias.jansson@metacon.com

This information is information that Metacon AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, at 08:00 CET on 19 November 2024.

About Metacon

Metacon AB (publ) develops and manufactures energy systems for the production of fossil-free "green" hydrogen. The products in the Reforming business area are based on a patented technology that generates hydrogen through so-called catalytic steam reforming of biogas or other substances. The development of Metacon's reforming products is carried out within the wholly-owned subsidiary Metacon S.A in Patras, Greece. The business is focused on catalytic process chemistry and advanced reformers for high-efficiency hydrogen production.

Metacon also offers complete electrolysis plants and integrated refuelling stations for green hydrogen, a large and globally growing area for production of green hydrogen. Electrolysis is a process in which a chemical reaction is driven to split water into hydrogen and oxygen by adding electricity. If the electricity used is fossil-free, hydrogen will also be fossil-free and climate-neutral. Green hydrogen can be used in the transport sector, basic industry and the real estate sector, among others, and lead to a better environment, climate and increased self-sufficiency in energy and vehicle fuel as a result. www.metacon.com

For further information please see:
www.metacon.com | X: @Metaconab | LinkedIn: www.linkedin.com/company/metaconab

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/metacon-ab/r/metacon-publishes-interim-report-for-q3-2024,c4068101

The following files are available for download:

https://mb.cision.com/Main/17030/4068101/3120355.pdf

DelaÌŠrsrapport Q3-2024 Eng

https://mb.cision.com/Public/17030/4068101/8a9bb285f4e4f2da.pdf

PRM Metacon Q3 eng

Cision View original content:https://www.prnewswire.co.uk/news-releases/metacon-publishes-interim-report-for-q3-2024-302309608.html

© 2024 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.